Yousif Capital Management LLC Sells 342 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Yousif Capital Management LLC lowered its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 12,644 shares of the specialty pharmaceutical company’s stock after selling 342 shares during the quarter. Yousif Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $1,570,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Range Financial Group LLC bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at approximately $917,000. First Citizens Bank & Trust Co. bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at approximately $318,000. UMB Bank n.a. increased its position in shares of Jazz Pharmaceuticals by 116.4% during the 1st quarter. UMB Bank n.a. now owns 673 shares of the specialty pharmaceutical company’s stock valued at $84,000 after purchasing an additional 362 shares during the last quarter. Radnor Capital Management LLC increased its position in shares of Jazz Pharmaceuticals by 7.8% during the 1st quarter. Radnor Capital Management LLC now owns 8,540 shares of the specialty pharmaceutical company’s stock valued at $1,060,000 after purchasing an additional 615 shares during the last quarter. Finally, Lmcg Investments LLC increased its position in shares of Jazz Pharmaceuticals by 63.6% during the 1st quarter. Lmcg Investments LLC now owns 74,370 shares of the specialty pharmaceutical company’s stock valued at $9,233,000 after purchasing an additional 28,907 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $109.64 on Tuesday. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a market capitalization of $6.63 billion, a price-to-earnings ratio of 15.44, a P/E/G ratio of 1.04 and a beta of 0.33. The stock has a fifty day simple moving average of $107.97 and a two-hundred day simple moving average of $120.45. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts’ expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the company earned $2.68 earnings per share. On average, analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $107.90, for a total value of $53,950.00. Following the completion of the sale, the chief executive officer now directly owns 438,473 shares in the company, valued at approximately $47,311,236.70. This trade represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Seamus Mulligan purchased 100,000 shares of the firm’s stock in a transaction on Friday, May 9th. The stock was acquired at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director now owns 100,000 shares of the company’s stock, valued at $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 3,000 shares of company stock worth $355,925 in the last three months. 4.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Morgan Stanley cut their price objective on Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. HC Wainwright upped their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Finally, Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $184.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.